HBV

Hepatitis B virus

HBV

Related Products

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

HBV Related Products (371)
Antibodies (2)

By Effects:	Inhibitors (335)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-113308AS

Taurolithocholic acid-d₄ sodium	Inhibitor	99.4%
Taurolithocholic acid-d₄ (sodium) is the deuterium labeled Taurolithocholic acid (sodium salt). Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.

HY-19447A

Besifovir Dipivoxil maleate	Inhibitor
Besifovir Dipivoxil maleate (LB80380 maleate) is an oral proagent of LB80317. Besifovir Dipivoxil maleate (LB80380 maleate) is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies^[2]

HY-144319

SHR5133	Inhibitor
SHR5133 is a highly potent, orally active HBV capsid assembly modulator. SHR5133 displays HBV DNA reduction (EC₅₀=26.6 nM).

HY-139574

Firzacorvir	Inhibitor
Firzacorvir is a cyclic sulfamide compound and modulates HBV core protein. Firzacorvir has anti-HBV activity with EC₅₀ < 1 μΜ.

HY-B0250A

Lamivudine salicylate	Inhibitor
Lamivudine (BCH-189) salicylate is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine salicylate can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.

HY-159160

HBV-IN-46	Inhibitor
HBV-IN-46 (compound 1.6) is an active metabolite. HBV-IN-46 is a HBV S-antigen inhibitor, with an EC₅₀ of 2.6 nM.

HY-145052

HBV-IN-9	Inhibitor
HBV-IN-9 is a potent HBsAg (HBV Surface antigen) inhibitor (IC₅₀=10 nM) and HBV DNA production inhibitor (IC₅₀=0.15 nM in HepG2.2.15 cells). From patent WO2018001952A1, example 20.

HY-149815

HBV-IN-33	Inhibitor
HBV-IN-33 (C-49), a HBV inhibitor, notably suppresses HBV replication in HepAD38, HepG2-HBV1.3 and HepG2-NTCP cells.

HY-168045

HBV-IN-48	Inhibitor
HBV-IN-48 is an HBV inhibitor. HBV-IN-48 has antiviral activity against HBV in HepDE19 cells, with an EC₅₀ value of 0.005 μM. HBV-IN-48 can reduce serum HBV DNA levels in mouse models of HBV infection.

HY-145871

BA38017	Inhibitor
BA38017 is a potent HBV core protein assembly modulator. BA38017 inhibits HBV replication with an EC₅₀ of 0.20 μM.

HY-147266A

Elebsiran	Inhibitor
Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections.

HY-126033

Sophoranol	Inhibitor
Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratory syncytial virus (RSV) with an IC₅₀ of 10.4 μg/mL.

HY-177654

Ozisiran	Inhibitor
Ozisiran, a siRNA, is a hepatitis B virus (HBV) RNA transcript reducer with antiviral activity.

HY-14404

MK-1220	Inhibitor
MK-1220 is a covalently reversible inhibitor of the hepatitis C virus (HCV) NS3/4A protease (NS3/4A protease) with a K_i of 0.02 nM. MK-1220 in cell models simulating viral replication exhibits EC₅₀s of 4 (with 10% fetal bovine serum) and 11 nM (50% normal human serum). MK-1220 can be used for the study of chronic hepatitis C virus infection.

HY-N6939R

Pseudolaric Acid B (Standard)	Inhibitor
Pseudolaric Acid B (Standard) is the analytical standard of Pseudolaric Acid B. This product is intended for research and analytical applications. Pseudolaric Acid B is an orally active diterpene acid. Pseudolaric Acid B has anti-fungal, anti-fertility, anti-angiogenesis and anticancer activity, and can induce tumor cell apoptosis and autophagy. In addition, Pseudolaric Acid B can inhibit the secretion of hepatitis B virus (HBV) and has immunosuppressive effect, selectively inhibiting the proliferation of T lymphocytes and the production of IL-2.

HY-Y0073R

4-Hydroxyacetophenone (Standard)	Inhibitor
4-Hydroxyacetophenone (Standard) is the analytical standard of 4-Hydroxyacetophenone. This product is intended for research and analytical applications. 4-Hydroxyacetophenone (P-hydroxyacetophenone) is a major hepatoprotective and choleretic compound found in Artemisia and Illicium plants, exhibiting antiviral and anti-inflammatory effects against hepatitis B virus. Additionally, 4-Hydroxyacetophenone inhibits cancer cell adhesion, invasion, and migration by remodeling actin. 4-Hydroxyacetophenone holds promise for research in the fields of inflammatory diseases and cancer.

HY-156272

HBV-IN-41	Inhibitor
HBV-IN-41 (compound 45) is a potent and orally active Hepatitis B Virus (HBV) inhibitor, with an EC₅₀ of 0.027μM.

HY-13623S1

Entecavir-¹³C₂,¹⁵N	Inhibitor
Entecavir-¹³C₂,¹⁵N (BMS200475-¹³C₂,¹⁵N; SQ34676-¹³C₂,¹⁵N) is a ¹³C- and ¹⁵N-labeled Entecavir (HY-13623). Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC₅₀ of 3.75 nM in HepG2 cell.

HY-109969

Z060228	Inhibitor
Z060228 is a capsid-targeting anti-HBV agent that inhibits HBV DNA replication in the supernatant of the HepG2.2.15 cell.

HY-145638X

GalNAc unconjugated/naked Xalnesiran	Inhibitor
GalNAc unconjugated/naked Xalnesiran is a non-GalNAc-conjugated Xalnesiran (HY-145638). Xalnesiran is siRNA for the study of chronic hepatitis B (HBV).

Name
Email *

	Sorry, but the email address you supplied was invalid.

HBV

HBV

HBV Related Products (371)

Antibodies (2)

HBV Related Products (371):